ANTIGEN IDENTIFICATION AND GENE DISCOVERY FOR LEISHMANIA VACCINE DEVELOPMENT

Show full item record

Title: ANTIGEN IDENTIFICATION AND GENE DISCOVERY FOR LEISHMANIA VACCINE DEVELOPMENT
Author: Campbell, Kimberly Suzanne
Description: ANTIGEN IDENTIFICATION AND GENE DISCOVERY FOR LEISHMANIA VACCINE DEVELOPMENT Publication No . _ _ _ _ _ _ _ _ _ _ _ _ _ Kimberly S . Campbell , Ph .D . The University of Texas Graduate School of Biomedical Sciences at Galveston , 2003 Supervisor : Lynn Soong Leishmania parasites are important human pathogens , with over twenty different species causing disease in millions of people . Currently , there is no effective vaccine against leishmaniasis . The solid immunity observed following recovery from cutaneous leishmaniasis in humans implies prevention of leishmaniasis through vaccination is feasible . The purpose of this dissertation is to identify potential targets for DNA vaccination capable of preventing cutaneous leishmaniasis . Given the complex nature of the parasite , we hypothesize that a multi -valent Leishmania DNA vaccine would provide long -term protection against multiple Leishmania species . DNA vaccination is a relatively new technology that offers advantages over conventional vaccines : they can elicit cellular responses , they are low in cost , ensure proper folding of the protein , produce the antigen over a long period of time , have the potential for long -lasting immunity , and can be used on immunocompromised individuals . Initially , we chose the P4 antigen for our DNA vaccine study since it was previously shown to protect mice in native protein form . Murine IL -12 and Leishmania heat shock protein 70 (HSP70 ) were chosen as adjuvants for their ability to stimulate a Th1 response , which is essential for protection against Leishmania infection in mouse models . We found that co -injection with plasmids encoding the L . amazonensis P4 gene and the IL -12 gene was able to protect susceptible mice against L . amazonensis but not against L . major . Conversely , we found that the P4 /HSP70 vaccine was able to protect mice against L . major but only delayed lesion development in L . amazonensis -infected mice . To identify additional antigen targets , we screened an L . amazonensis cDNA expression library and identified a novel antigen , which we named LAWD (Leishmania antigenic WD protein ) . Recombinant LAWD stimulated CD4+ T cells from infected mice to produce high levels vi of a Th1 cytokine , suggesting its potential for DNA vaccination . The LAWD gene , when co -administered with the IL -12 gene , was able to significantly delay lesion development and reduced parasite burdens in susceptible mice challenged with L . amazonensis . Results presented here demonstrate that DNA vaccination is an effective way to protect mice against L . amazonensis and has the potential to cross -protect against evolutionarily diverse Leishmania
URI: http : / /hdl .handle .net /2249 .1 /35661
Date: 2011-04-27

Citation

ANTIGEN IDENTIFICATION AND GENE DISCOVERY FOR LEISHMANIA VACCINE DEVELOPMENT. Available electronically from http : / /hdl .handle .net /2249 .1 /35661 .

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show full item record

Search DSpace

Advanced Search

Browse